Literature DB >> 16119496

Seizures, metabolic acidosis and coma resulting from acute isoniazid intoxication.

I Topcu1, E A Yentur, A Kefi, N Z Ekici, M Sakarya.   

Abstract

Isoniazid is an anti-tuberculosis drug, used commonly for treatment and prophylaxis of tuberculosis. Acute isoniazid intoxication is characterized by a clinical triad consisting of metabolic acidosis resistant to treatment with sodium bicarbonate, seizures which may be fatal and refractory to standard anticonvulsant therapy, and coma. Treatment requires admission to the intensive care unit for ventilatory support, management of seizures and metabolic acidosis. Pyridoxine, in a dose equivalent to the amount of isoniazid ingested, is the only effective antidote. We report the successful treatment of two isoniazid intoxication cases: the case of a child developing an accidental acute isoniazid intoxication and an adult case of isoniazid intoxication with the intent of suicide.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16119496     DOI: 10.1177/0310057X0503300416

Source DB:  PubMed          Journal:  Anaesth Intensive Care        ISSN: 0310-057X            Impact factor:   1.669


  4 in total

Review 1.  Central nervous system tuberculosis.

Authors:  A Cherian; S V Thomas
Journal:  Afr Health Sci       Date:  2011-03       Impact factor: 0.927

2.  Oral pyridoxine can substitute for intravenous pyridoxine in managing patients with severe poisoning with isoniazid and rifampicin fixed dose combination tablets: a case report.

Authors:  M D S A Dilrukshi; C A P Ratnayake; C A Gnanathasan
Journal:  BMC Res Notes       Date:  2017-08-08

3.  Fatal poisoning by isoniazid and rifampicin.

Authors:  A Sridhar; Y Sandeep; C Krishnakishore; P Sriramnaveen; Y Manjusha; V Sivakumar
Journal:  Indian J Nephrol       Date:  2012-09

Review 4.  Diabetes and tuberculosis: a syndemic complicated by COVID-19.

Authors:  Violeta Antonio-Arques; Josep Franch-Nadal; Joan A Caylà
Journal:  Med Clin (Barc)       Date:  2021-05-06       Impact factor: 1.725

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.